Organon & Co. Common Stock (OGN)
OGN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/0001628280-26-011125-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OGN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001821825 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.2B |
| Net income | $187.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | 3.0% |
| Operating margin | Operating income not reported |
| Revenue growth | -2.9% |
| Cash | $574.0M |
| Total assets | $12.9B |
| P/E (computed) | 19.5× |
| P/S (computed) | 0.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $1.5B cash; operating cash flow $210.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 262,621,584 (2026-10-23); 259,982,912 a year earlier; 255,606,461 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $855K, sold $553K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6B | $164.0M | $370.0M | $1.5B | $8.6B | $6.1B | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $1.6B | $108.0M | $107.0M | $1.1B | $8.6B | $6.1B | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | $1.5B | $146.0M | $225.0M | $1.1B | $8.6B | $6.2B | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $1.5B | -$205.0M | $141.0M | $574.0M | $8.6B | $6.2B | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $1.6B | $160.0M | $264.0M | $672.0M | $8.8B | $6.3B | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $1.6B | $145.0M | $220.0M | $599.0M | $8.9B | $6.3B | 10-Q 2026-07-31 |
| Q1 2025 2025-03-31 | $1.5B | $87.0M | $75.0M | $547.0M | $9.0B | $6.3B | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $1.6B | $109.0M | $390.0M | $675.0M | $8.9B | $6.4B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | DRS | 2020-11-02 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report FORM 8-K | 8-K | 2026-10-30 |
| Latest proxy | DEFA14A | 2026-07-17 |
Source: SEC EDGAR submissions feed, 466 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.2% |
| 1 month | +0.9% |
| 3 months | +1.3% |
| Year to date | +93.9% |
| 1 year | +82.4% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $39.26 | -3.01% | $3.9B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier